Kaposi's sarcoma in an Ankylosing Spondylitis patient treated with Anti-Tumor Necrosis Factor-Alpha (Anti-TNF-α) Therapy

Year 2022, Volume: 4 Issue: 1, 49 - 53, 29.01.2022

Selda Hakbilen , Dilek Tezcan , Sema Yilmaz

https://doi.org/10.46310/tjim.945846

Abstract

Tumor necrosis factor-alpha (TNF-α) inhibitors are immunosuppressive agents used in a variety of inflammatory diseases, including rheumatoid arthritis (RA), spondyloarthritis, psoriasis, and inflammatory bowel disease (IBD). Kaposi’s sarcoma (KS) is an angioproliferative disease associated with the human herpes virus 8 (HHV-8). We present a 46-year-old male patient with ankylosing spondylitis (AS) treated with TNF-α inhibitor and developed KS during follow-up. The coexistence of anti-TNF-α treatment with KS is a rare condition. This case is presented to address this rare association. Therefore, keeping in mind KS, which is a type of skin tumor, in such HIV-negative patients in whom immunosuppressive agents are initiated, is essential in terms of early diagnosis, treatment, and prevention of complications.

Keywords

Tumor necrosis factor-alpha inhibitors, Kaposi, ankylosing spondylitis

References

• Acurcio FA, Guerra Junior AA, da Silva MRR, Pereira RG, Godman B, Bennie M, Nedjar H, Rahme E. Comparative persistence of anti-tumor necrosis factor therapy in ankylosing spondylitis patients: a multicenter international study. Curr Med Res Opin. 2020 Apr;36(4):677-86. doi: 10.1080/03007995.2020.1722945.
• Koo S, Marty FM, Baden LR. Infectious complications associated with immunomodulating biologic agents. Hematol Oncol Clin North Am. 2011 Feb;25(1):117-38. doi: 10.1016/j.hoc.2010.11.009.
• Beutler B. TNF, immunity and inflammatory disease: lessons of the past decade. J Investig Med. 1995 Jun;43(3):227-35.
• García-Doval I, Hernández MV, Vanaclocha F, Sellas A, de la Cueva P, Montero D; BIOBADADERM and BIOBADASER study groups. Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts. Br J Dermatol. 2017 Mar;176(3):643-9. doi: 10.1111/bjd.14776.
• Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med. 1998 Apr 2;338(14):948-54. doi: 10.1056/ NEJM199804023381403.
• Gao SJ, Kingsley L, Hoover DR, Spira TJ, Rinaldo CR, Saah A, Phair J, Detels R, Parry P, Chang Y, Moore PS. Seroconversion to antibodies against Kaposi’s sarcoma- associated herpesvirus-related latent nuclear antigens before the development of Kaposi’s sarcoma. N Engl J Med. 1996 Jul 25;335(4):233-41. doi: 10.1056/NEJM199607253350403.
• Baykal C, Atci T, Buyukbabani N, Kutlay A. The Spectrum of Underlying Causes of Iatrogenic Kaposi’s Sarcoma in a Large Series: A Retrospective Study. Indian J Dermatol. 2019 Sep-Oct;64(5):392-399. doi: 10.4103/ijd.IJD_217_18.
• Klepp O, Dahl O, Stenwig JT. Association of Kaposi’s sarcoma and prior immunosuppressive therapy: a 5-year material of Kaposi’s sarcoma in Norway. Cancer. 1978 Dec;42(6):2626-30.
• Mariappan AL, Desai S, Locante A, Desai P, Quraishi J. Iatrogenic Kaposi Sarcoma Precipitated by Anti-Tumor Necrosis Factor-Alpha (Anti-TNF-α) Therapy. Cureus. 2021 Feb 16;13(2):e13384. doi: 10.7759/cureus.13384.
• Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää- Dahlqvist S, Saxne T, Klareskog L. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum. 2009 Nov;60(11):3180- 9. doi: 10.1002/art.24941.
• Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R, Walsh C, Lawson R, Reynolds A, Emery P. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011 Nov;70(11):1895-904. doi: 10.1136/ard.2010.149419.
• Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011 Feb;20(2):119-30. doi: 10.1002/pds.2046.
• Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007 Sep;56(9):2886- 95. doi: 10.1002/art.22864.
• Amari W, Zeringue AL, McDonald JR, Caplan L, Eisen SA, Ranganathan P. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford). 2011 Aug;50(8):1431-9. doi: 10.1093/rheumatology/ker113.
• Atzeni F, Carletto A, Foti R, Sebastiani M, Panetta V, Salaffi F, Bonitta G, Iannone F, Gremese E, Govoni M, Marchesoni A, Favalli EG, Gorla R, Ramonda R, Sarzi- Puttini P, Ferraccioli G, Lapadula G; GISEA group. Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. Joint Bone Spine. 2018 Jul;85(4):455-9. doi: 10.1016/j.jbspin.2017.08.003.
• Hellgren K, Dreyer L, Arkema EV, Glintborg B, Jacobsson LT, Kristensen LE, Feltelius N, Hetland ML, Askling J; ARTIS Study Group, For the DANBIO Study Group. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers. Ann Rheum Dis. 2017 Jan;76(1):105-11. doi: 10.1136/annrheumdis-2016-209270.
• Martínez-Martínez ML, Pérez-García LJ, Escario- Travesedo E, Ribera-Vaquerizo PA. Kaposi sarcoma associated with infliximab treatment. Actas Dermosifiliogr. 2010 Jun;101(5):462-4 (in Spanish).
• Ursini F, Naty S, Mazzei V, Spagnolo F, Grembiale RD. Kaposi’s sarcoma in a psoriatic arthritis patient treated with infliximab. Int Immunopharmacol. 2010 Jul;10(7):827-8. doi: 10.1016/j.intimp.2010.04.016.
• Vural S, Gündogdu M, Akay BN, Korkmaz P, Sanli H, Heper AO, Kundakçi N. Aggressive Kaposi’s Sarcoma Associated With Golimumab Therapy. Arch Rheumatol. 2018 Jan 29;33(3):384-6. doi: 10.5606/ArchRheumatol.2018.6695.
• Cohen CD, Horster S, Sander CA, Bogner JR. Kaposi’s sarcoma associated with tumour necrosis factor alpha neutralising therapy. Ann Rheum Dis. 2003 Jul;62(7):684. doi: 10.1136/ard.62.7.684.
• Kuttikat A, Joshi A, Saeed I, Chakravarty K. Kaposi sarcoma in a patient with giant cell arteritis. Dermatol Online J. 2006 Oct 31;12(6):16.
• Amadu V, Satta R, Montesu MA, Cottoni F. Kaposi’s sarcoma associated with treatment with adalimumab. Dermatol Ther. Nov-Dec 2012;25(6):619-20. doi: 10.1111/j.1529-8019.2012.01523.x.
• Bret J, Hernandez J, Aquilina C, Zabraniecki L, Fournie B. Kaposi’s disease in a patient on adalimumab for rheumatoid arthritis. Joint Bone Spine. 2009 Dec;76(6):721-2. doi: 10.1016/j.jbspin.2009.10.006.
• Hamzaoui L, Kilani H, Bouassida M, Mahmoudi M, Chalbi E, Siai K, Ezzine H, Touinsi H, Azzouz MM, Sassi S. Iatrogenic colorectal Kaposi sarcoma complicating a refractory ulcerative colitis in a human immunodeficiency negative-virus patient. Pan Afr Med J. 2013 Aug 29;15:154. doi: 10.11604/pamj.2013.15.154.2988.
• Windon AL, Shroff SG. Iatrogenic Kaposi’s Sarcoma in an HIV-Negative Young Male With Crohn’s Disease and IgA Nephropathy: A Case Report and Brief Review of the Literature. Int J Surg Pathol. 2018 May;26(3):276-82. doi: 10.1177/1066896917736610.
• Bergler-Czop B, Brzezińska-Wcisło L, Kolanko M. Iatrogenic Kaposi’s sarcoma following therapy for rheumatoid arthritis. Postepy Dermatol Alergol. 2016 Apr;33(2):149-51. doi: 10.5114/ada.2016.59163.